Back
AbbVie Inc (ABBV)
BiotechnologyABBV · NEW YORK STOCK EXCHANGE, INC. · USD
New to investing? How to read this page →$265.73
+0.42%Weekly undervalued picks (like ABBV)
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$2.38
ROE
Gross margin
72.0%
Debt/Equity
Revenue growth
12.4%
P/B ratio
Beta
Forward P/E
AbbVie Inc — company intelligence
Earnings surprises
Q2 2026$3.65 vs $3.68 est-0.7%
Q1 2026$2.65 vs $2.65 est+0.2%
Q4 2025$2.71 vs $2.71 est+0.2%
Q3 2025$1.86 vs $1.81 est+2.7%
Analyst consensus · 38 analysts
31 Buy7 Hold0 Sell
Updated Aug 25, 2026
Insider activity · 90 days
2 buys0 sellsnet +196 shares
Quaggin Susan EBuy 62 · Jun 30, 2026
RAPP EDWARD JBuy 134 · Jun 30, 2026
Recent SEC filings
4 — Insider transaction reportAug 18, 2026
8-K — Material event reportAug 18, 2026
8-K — Material event reportAug 5, 2026
Latest news
Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $303 — Benzinga · 5d ago
Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $300 — Benzinga · 1w ago
Wolfe Research Upgrades AbbVie (ABBV) — Fintel · 1w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks (like ABBV)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.